Global Genitourinary Drugs Market is Segmented By Disease Type(Erectile dysfunction, Gonorrhoea, Genital Herpes, Urinary tract infections, Urinary Incontinence, Glomerulonephritis, Chronic renal failure and Other), By Drug Type(Hormonal Therapy, Impotence Agents, Uterine Relaxants, Urinary, Antispasmodics, Urinary pH Modifiers, Uterine Stimulants and Miscellaneous Genitourinary Tract Agents), By Distribution Channel(Hospital Pharmacy, Pharmacy Stores and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Genitourinary Drugs Market Size
Global Genitourinary Drugs Market reached US$ 31,220.0 million in 2023 and is expected to reach US$ 35,518.8 million by 2031, growing at a CAGR of 1.6% during the forecast period 2024-2031.
The genitourinary tract includes the urinary and genital organs. Various conditions, such as urinary tract infections and kidney problems, may affect the genitourinary tract.
Genitourinary drugs are used to treat disorders affecting the kidneys, bladder, ureters, and urethra. For long, patients suffering from disorders and infections related to genitourinary systems have been depending on steroids and immunosuppressants which are chemically synthesized and may reciprocate with some serious side effects such as insomnia, acne, nausea, vomiting, and diarrhea.
As a result, patients are turning to biological drugs that not only cause fewer to no side effects but are also more effective in the treatment of genitourinary infections.
Market Scope
|
Metrics |
Details |
|
CAGR |
1.6% |
|
Market Size Available for Years |
2022-2031 |
|
Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Disease Type, Drug Type, Distribution Channel |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Largest Region |
North America |
|
Fastest Growing Region |
Asia-Pacific |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report Request for Sample
Market Dynamics: Drivers & Restraints
Growing prevalence of genitourinary disorders
The growing prevalence of genitourinary disorders and the increasing number of pipeline drugs are expected to widen the market growth, globally. The increasing number of individuals with genitourinary diseases will increase the demand for using proper and effective medication which will rise the demand for the drugs.
For instance, according to The Continence Foundation of Australia, it is estimated that urinary incontinence affects up to 10% of Australian men and up to 38% of Australian women. 80% of those with urinary incontinence in the community are women. Over half of women living in the community with urinary incontinence are aged under 50 years. Thus, the above factors are expected to drive the market growth.
Increasing number of counterfeit drugs
The presence of many alternative drugs that imitate the original ones is expected to hinder the market growth. The pharmaceutical companies that are investing in the research and development of genitourinary drugs may face challenges and experience loss due to these counterfeit drugs.
For more details on this report – Request for Sample
Market Segment Analysis
The global genitourinary drugs market is segmented based on disease type, drug type, distribution channel and region.
Hormonal therapy segment is expected to dominate the market share
Many genitourinary disorders, including breast and prostate cancer as well as hormonal imbalances that impact the reproductive system, can be effectively treated with hormone therapy. These treatments can dramatically reduces symptoms associated to hormones or tumor growth. Hormonal treatments are flexible and can be applied to genitourinary illnesses of various stages and types.
By reducing testosterone levels, for instance, they are essential in the management of prostate cancer as it reduces its growth. Likewise, hormonal therapies alleviate symptoms of illnesses such as endometriosis and menopausal symptoms by controlling hormone levels. Thus, the above factors are expected to hold the segment in the dominant position.
Market Geographical Analysis
North America is expected to hold a significant position in the genitourinary drugs market share
North America has been holding the dominant position in the market share. The rise in genitourinary disease cases, the growing need for improved treatments and therapies of genitourinary diseases and increasing awareness about genitourinary diseases is driving the growth of the market in the region. A quarter to a third of men and women in the U.S. suffer from urinary incontinence.
For instance, according to the UF Department of Urology, it is estimated that Kidney stone disease affects approximately one in every 500 individuals in the United States each year. Over a lifetime, 1 in 8 men and 1 in 16 women will develop this disease.
Additionally, according to a report by the Urology Care Foundation, Urinary Tract Infection is one of the most common infection among the individuals in U.S. UTIs are the second most common type of infection in the body and are the reason for more than 8 million visits to the doctor each year. About 10 in 25 women and 3 in 25 men will have symptoms of a UTI during their lifetime. Thus, the above factors are expected to drive the market growth in the region.
Market Segmentation
By Disease Type
- Erectile Dysfunction
- Gonorrhoea
- Genital Herpes
- Urinary Tract Infections
- Urinary Incontinence
- Glomerulonephritis
- Chronic Renal Failure
- Other
By Drug Type
- Hormonal Therapy
- Impotence Agents
- Uterine Relaxants
- Urinary Antispasmodics
- Urinary pH Modifiers
- Uterine Stimulants
- Miscellaneous Genitourinary Tract Agents
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy Stores
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer Inc., Eli Lilly and Company, MANUS AKTTEVA BIOPHARMA LLP. Astellas Pharma Inc., Jubilant Cadista Pharmaceuticals Inc., Bayer AG, Endo International Plc, Teva Pharmaceuticals USA, Inc., Astellas Pharma US, Inc. and TAIHO PHARMACEUTICAL CO., LTD. among others.
Why Purchase the Report?
- To visualize the global genitourinary drugs market segmentation based on disease type, drug type, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of genitourinary drugs Market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global genitourinary drugs market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
